lapatinib has been researched along with Cancer of Prostate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W | 1 |
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Awasthi, S; Ezelle, H; Hamburger, AW; Hassel, BA | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Benowitz, S | 1 |
| Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Armstrong, AJ; Crane, JM; George, DJ; Godley, PA; Grigson, G; Kim, WY; Moore, DT; Morris, K; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, CP; Whang, YE | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Bubley, GJ; Carducci, M; Chen, YH; Dipaola, R; Huang, W; Kolesar, J; Liu, G; Pins, M; Stein, M; Wilding, G | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
4 trial(s) available for lapatinib and Cancer of Prostate
| Article | Year |
|---|---|
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2010 |
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Castration; ErbB Receptors; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate | 2013 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2013 |
8 other study(ies) available for lapatinib and Cancer of Prostate
| Article | Year |
|---|---|
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference | 2021 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Androgens; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Androgen; RNA-Binding Proteins; Signal Transduction | 2015 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |